BR0318535A - composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada - Google Patents

composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada

Info

Publication number
BR0318535A
BR0318535A BRPI0318535-4A BR0318535A BR0318535A BR 0318535 A BR0318535 A BR 0318535A BR 0318535 A BR0318535 A BR 0318535A BR 0318535 A BR0318535 A BR 0318535A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
controlled
formulation
controlled release
lactam antibiotic
Prior art date
Application number
BRPI0318535-4A
Other languages
English (en)
Inventor
Shailesh Bhamare
Indu Bhushan
Sen Himadri
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR0318535A publication Critical patent/BR0318535A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA O ENVIO CONTROLADO DE DROGA, PROCESSO PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA E COMPOSIçãO DE LIBERAçãO CONTROLADA". A presente invenção se refere a uma composição farmacêutica para o envio controlado de droga compreendendo um antibiótico <225>-lactam os hidratos, sais ou ésteres farmaceuticamente aceitáveis do mesmo, e um ou mais carbómeros. A formulação de antibiótico <225>-lactam acima, evita as limitações da forma de liberação controlada de <225>-lactam conhecida, que foi observada ser ou complexa ou anti-económica de se obter, necessitando de múltiplas fases e/ou de revestimento seletivo, ou apresentar falha em alcançar a liberação controlada desejada para a forma de dosagem de uma vez ao dia. Também importante, na forma de antibiótico <225>-lactam do polímero de coeficiente controlado, onde a C~ max~ da formulação é substancialmente a mesma daquela de uma dose simples da formulação de liberação imediata. Ainda de forma vantajosa, a formulação alcança um coeficiente de polímero controlado onde T > MIC para a formulação é de mais de 17 horas quando MIC é 0,25 mcg/mL e mais de 10 horas quando MIC é 2 mcg/mL. A forma de antibiótico <225>-lactam acima é assim orientada para servir como a forma de liberação controlada mais desejada e simples e de custo eficaz, adequada para a administração uma vez ao dia.
BRPI0318535-4A 2003-09-30 2003-09-30 composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada BR0318535A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000326 WO2005030178A1 (en) 2003-09-30 2003-09-30 Extended release formulation of beta-lactam antibiotics

Publications (1)

Publication Number Publication Date
BR0318535A true BR0318535A (pt) 2006-09-12

Family

ID=34385765

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318535-4A BR0318535A (pt) 2003-09-30 2003-09-30 composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada

Country Status (6)

Country Link
US (1) US20060233878A1 (pt)
EP (1) EP1667661A1 (pt)
AU (1) AU2003290394A1 (pt)
BR (1) BR0318535A (pt)
MX (1) MXPA06002841A (pt)
WO (1) WO2005030178A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006018A (es) 2004-11-30 2007-06-07 Astellas Pharma Inc Suspension farmaceutica oral novedosa de cristal de cefdinir.
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CA2635378C (en) * 2005-12-08 2015-06-16 Advancis Pharmaceutical Corporation Pharmaceutical compositions and methods for improved bacterial eradication
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
TR201001417A1 (tr) 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
EP2906203B1 (en) 2012-10-11 2018-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent cefdinir formulation
CA2910421A1 (en) * 2013-05-07 2014-11-13 Mcmaster University Inhibitors of metallo-.beta.-lactamase-enzymes
EP2926815A1 (en) 2014-04-03 2015-10-07 Institut Curie New derivatives of cephalosporin for treating cancer
CN109293680B (zh) * 2018-09-26 2020-06-16 华北制药河北华民药业有限责任公司 一种头孢哌酮酸的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128902C (pt) * 1960-06-06
GB1312918A (en) * 1969-07-08 1973-04-11 Beecham Group Ltd Veterinary treatment
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition

Also Published As

Publication number Publication date
WO2005030178A1 (en) 2005-04-07
AU2003290394A1 (en) 2005-04-14
MXPA06002841A (es) 2006-06-14
EP1667661A1 (en) 2006-06-14
US20060233878A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
JP6764913B2 (ja) ロキソプロフェンを含有する医薬組成物＜参＞
BR0109875A (pt) Tratamento de doenças respiratórias
WO2004108162A3 (en) Controlled release pharmaceutical composition
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2012505883A5 (pt)
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
KR20150134176A (ko) 안정성을 향상시킨 로티고틴 함유 경피흡수제제
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
KR20130070307A (ko) 국소 투여용 지속형 치주염 치료제 조성물
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
CN102137664B (zh) 具有被边界隔开的有效成分的固体药物制剂
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
EP4245303A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTRATION THEREOF
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.